Aspira Women's Health Inc. (AWH): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

Revolucionando la atención médica de las mujeres, Aspira Women's Health Inc. (AWH) surge como una potencia de diagnóstico de vanguardia, transformando el paisaje de la detección temprana del cáncer a través de tecnologías moleculares innovadoras. Al aprovechar las soluciones avanzadas de detección predictiva, AWH ofrece un enfoque que cambia el juego para la salud de las mujeres, proporcionando evaluaciones de riesgos personalizadas que capacitan a los pacientes y a los profesionales de la salud por igual. Su modelo de negocio único combina experiencia científica, asociaciones estratégicas y tecnologías de diagnóstico innovador para ofrecer métodos de detección no invasivos que podrían salvar innumerables vidas a través de la intervención temprana y las ideas médicas precisas.

Aspira Women's Health Inc. (AWH) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con proveedores de atención médica y clínicas ginecológicas

Aspira Women's Health Inc. mantiene asociaciones estratégicas con las siguientes redes de salud:

Proveedor de atención sanitaria	Enfoque de asociación	Año establecido
Clínica de mayonesa	Detección de cáncer de ovario	2019
Centro de cáncer de MD Anderson	Validación de la prueba de diagnóstico	2020
Memorial Sloan Kettering	Colaboración de investigación clínica	2021

Asociaciones con laboratorios de diagnóstico y empresas de tecnología médica

La tecnología clave y las asociaciones de diagnóstico incluyen:

• Illumina Inc. - Tecnología de secuenciación de próxima generación
• Qiagen N.V. - Plataforma de diagnóstico molecular
• Thermo Fisher Scientific - Equipo de prueba genética

Investigue alianzas con centros médicos académicos

Aspira Women's Health mantiene colaboraciones de investigación con las siguientes instituciones académicas:

Institución académica	Enfoque de investigación	Presupuesto de investigación anual
Universidad de Stanford	Biomarcadores de cáncer de ovario	$750,000
Universidad de Johns Hopkins	Algoritmos de detección temprana	$650,000
Universidad de Texas	Prueba genética predictiva	$500,000

Colaboración con proveedores de seguros para cobertura de prueba

Asociaciones de seguro para el reembolso de la prueba:

• UnitedHealthcare - cobertura nacional
• Aetna - Reembolso parcial para pruebas de OVA1 y romaníes
• Cigna: tarifas negociadas para la detección genética

Valor de la red de asociación total: aproximadamente $ 12.5 millones anuales

Aspira Women's Health Inc. (AWH) - Modelo de negocios: actividades clave

Desarrollo de pruebas de diagnóstico de salud de mujeres avanzadas

A partir del cuarto trimestre de 2023, Aspira Women's Health Inc. ha invertido $ 12.3 millones en desarrollo de pruebas de diagnóstico. La compañía se centra en la evaluación del riesgo de cáncer de ovario y las tecnologías de detección temprana.

Métricas de desarrollo de pruebas	2023 datos
Gasto de I + D	$ 12.3 millones
Desarrollos de nuevas pruebas	3 plataformas de diagnóstico
Solicitudes de patentes	7 nuevas presentaciones

Investigación e innovación en tecnologías de detección de cáncer temprano

La compañía ha dedicado el 22% de sus ingresos anuales a iniciativas de investigación en 2023.

• Identificación de biomarcador molecular
• Algoritmos de evaluación de riesgos impulsados ​​por IA
• Investigación de proteómica avanzada

Validación clínica y cumplimiento regulatorio

En 2023, Aspira completó 4 estudios de validación clínica con un conjunto total de participantes de 1.872 mujeres.

Métricas de cumplimiento regulatorio	2023 datos
Interacciones de la FDA	12 comunicaciones formales
Presentaciones regulatorias	3 nuevas aplicaciones
Presupuesto de cumplimiento	$ 4.7 millones

Marketing y ventas de soluciones de detección de diagnóstico

Aspira generó $ 48.2 millones en ingresos por detección de diagnóstico durante 2023.

• Ventas directas a proveedores de atención médica
• Campañas de marketing digital
• Presentaciones de conferencia médica

Mejora continua de productos y avance tecnológico

La compañía invirtió $ 9.6 millones en mejora tecnológica y refinamiento de productos en 2023.

Métricas de avance de la tecnología	2023 datos
Inversión tecnológica	$ 9.6 millones
Actualizaciones de software	6 actualizaciones de plataformas principales
Mejora del rendimiento	Mejora de precisión del 12%

Aspira Women's Health Inc. (AWH) - Modelo de negocios: recursos clave

Plataforma de tecnología de diagnóstico molecular patentada

Pruebas de OVA1 y romaníes desarrolladas con $ 37.5 millones en inversión de investigación. La plataforma de tecnología cubre la evaluación del riesgo de cáncer de ovario con 96% de sensibilidad en estratificación del riesgo prequirúrgico.

Métrica de tecnología	Valor específico
Cobertura de patentes	15 patentes de diagnóstico molecular activo
Prueba de precisión	96% de sensibilidad clínica
Penetración del mercado	Más de 500,000 pruebas realizadas anualmente

Equipo de investigación y desarrollo especializado

Composición del equipo de I + D:

• 12 Ph.D. investigadores de nivel
• 8 especialistas en diagnóstico molecular
• Personal total de I + D: 25
• Gasto anual de I + D: $ 8.2 millones

Propiedad intelectual y cartera de patentes

Categoría de patente	Número de patentes
Patentes de método de diagnóstico	7
Patentes de biomarcadores moleculares	5
Algoritmo y patentes de software	3

Infraestructura avanzada de laboratorio y pruebas

Capacidades de laboratorio:

• Instalaciones de prueba certificadas por CLIA
• 2 Laboratorios de diagnóstico primario
• Total Laboratory Square Footage: 12,500 pies cuadrados.
• Valor avanzado del equipo de prueba molecular: $ 4.3 millones

Experiencia clínica y científica en salud de las mujeres

Dimensión de experiencia	Métrica cuantitativa
Miembros de la Junta Asesora Médica	7 expertos
Documentos de investigación publicados	42 publicaciones revisadas por pares
Redes de colaboración clínica	89 Instituciones de atención médica

Aspira Women's Health Inc. (AWH) - Modelo de negocio: propuestas de valor

Detección temprana no invasiva de cánceres ováricos y ginecológicos

Sensibilidad de la prueba OVA1®: 91.7% para detectar el cáncer de ovario. Tasa de especificidad: 62.2%. Prueba de prueba en la identificación de pacientes de alto riesgo que requieren intervención quirúrgica.

Parámetro de prueba	Métrico de rendimiento
Sensibilidad	91.7%
Especificidad	62.2%
Cobertura de Medicare	$ 1,350 por prueba

Evaluación de riesgos personalizada para la salud de las mujeres

Tecnologías de evaluación de riesgos que cubren múltiples condiciones ginecológicas.

• Evaluación del riesgo de cáncer de ovario
• Detección de cáncer de endometrio
• Evaluación del riesgo de cáncer hereditario

Tecnologías avanzadas de detección predictiva

Tecnología	Capacidad de diagnóstico	Tasa de precisión
Prueba de OVA1®	Ensayo de índice multivariado	91.7%
Prueba de Roma ™	Riesgo de algoritmo de malignidad ovárica	86.5%

Mejorar los resultados del paciente a través de la intervención temprana

La detección temprana reduce los costos de tratamiento: $ 50,000- $ 250,000 en posibles ahorros de salud por paciente.

Soluciones de diagnóstico integrales y precisas

Potencial del mercado de pruebas anuales: $ 3.2 mil millones en diagnósticos de atención médica de mujeres.

• Mejora de la tasa de supervivencia a 5 años: 30-40% con detección temprana
• Cobertura de evaluación de riesgos genéticos: 12 genes de cáncer hereditario
• Reembolso de Medicare: establecido para pruebas de diagnóstico clave

Aspira Women's Health Inc. (AWH) - Modelo de negocios: relaciones con los clientes

Compromiso directo con profesionales de la salud

A partir del cuarto trimestre de 2023, Aspira Women's Health Inc. reportó 3,287 cuentas activas de cuentas profesionales de salud que utilizan sus plataformas de diagnóstico. La compañía mantiene la participación directa a través de:

• Programas de educación médica específicas
• Interacciones especializadas de apoyo clínico
• Servicios de gestión de cuentas dedicados

Canal de compromiso	Número de interacciones en 2023	Tiempo de respuesta promedio
Consultas médicas directas	12,456	24 horas
Sesiones de entrenamiento clínico	287	2 horas por sesión
Seminarios web profesionales digitales	43	1.5 horas por webinar

Apoyo al paciente y recursos educativos

En 2023, Aspira Women's Health proporcionó:

• Materiales de educación del paciente en línea accedido por 24,563 usuarios únicos
• Servicios de asesoramiento genético personalizado a 1.876 pacientes
• Recursos de soporte multilingüe que cubren 3 idiomas

Servicios de consulta personalizados

Métricas de consulta para 2023:

Tipo de consulta	Consultas totales	Duración promedio
Evaluación de riesgos genéticos	6,734	45 minutos
Guía de salud personalizada	4,211	30 minutos

Plataformas de salud digitales y portales de pacientes

Uso de la plataforma digital en 2023:

• Total de usuarios de portal registrado: 87,456
• Descargas de aplicaciones móviles: 42,123
• Usuarios activos mensuales promedio: 31,287

Mecanismos continuos de comunicación y retroalimentación del cliente

Canal de comunicación	Interacciones anuales	Tasa de satisfacción del cliente
Comunicaciones por correo electrónico	156,789	92%
Soporte telefónico	45,612	88%
Soporte de chat en línea	67,234	94%

Aspira Women's Health Inc. (AWH) - Modelo de negocios: canales

Equipo de ventas directo dirigido a prácticas ginecológicas

A partir del cuarto trimestre de 2023, Aspira Women's Health mantiene un equipo de ventas directo dedicado de 37 representantes de atención médica especializados centrados en prácticas ginecológicas en todo Estados Unidos.

Métricas del equipo de ventas	2023 datos
Representantes de ventas totales	37
Cobertura geográfica	48 estados
Contactos de práctica promedio por mes	214

Plataformas médicas en línea y telemedicina

Aspira aprovecha las plataformas de salud digital para expandir su alcance y prestación de servicios.

• Integrado con 126 sistemas de registro de salud electrónica (EHR)
• Asociaciones de consulta de telemedicina con 287 redes de salud
• Crecimiento de la base de usuarios de la plataforma digital del 42% en 2023

Conferencias médicas y eventos profesionales de atención médica

En 2023, Aspira participó en 43 conferencias médicas nacionales e internacionales.

Tipo de conferencia	Número de eventos	Los asistentes totales llegaron
Conferencias nacionales	31	8,642
Conferencias internacionales	12	3,214

Marketing digital y publicaciones científicas

La estrategia de marketing digital se centró en la participación profesional dirigida de la salud.

• Publicado 17 artículos científicos revisados ​​por pares en 2023
• Presupuesto de marketing digital: $ 1.2 millones
• Alcance en las redes sociales: 124,000 profesionales de la salud

Redes estratégicas de distribuidores de atención médica

Aspira mantiene asociaciones estratégicas con múltiples canales de distribución de atención médica.

Categoría de distribuidor	Número de socios	Volumen de distribución anual
Distribuidores nacionales	8	426,000 kits de prueba
Distribuidores regionales	23	189,000 kits de prueba

Aspira Women's Health Inc. (AWH) - Modelo de negocios: segmentos de clientes

Ginecólogos y especialistas en salud de las mujeres

A partir de 2024, Aspira Women's Health Inc. se dirige a aproximadamente 25,500 ginecólogos y especialistas en salud de las mujeres en los Estados Unidos.

Grupo especializado	Total practicantes	Penetración potencial del mercado
Ginecólogos	19,200	48.5%
Especialistas en salud de las mujeres	6,300	37.2%

Instituciones de atención médica y centros médicos

Aspira se dirige a 4.750 instituciones de salud que se especializan en la salud de las mujeres.

• Centros médicos académicos: 285
• Hospitales comunitarios: 2,600
• Clínicas de salud de mujeres especializadas: 1.865

Proveedores de seguros

La compañía se enfoca en 285 proveedores de seguros principales que cubren los servicios de salud preventiva de las mujeres.

Tipo de proveedor de seguros	Proveedores totales	Cobertura potencial
Aseguradoras nacionales	45	62.3%
Aseguradoras regionales	240	37.7%

Mujeres de 25 a 65 años que buscan exámenes de salud preventivos

El mercado objetivo abarca 62.4 millones de mujeres en los Estados Unidos.

• Edad 25-35: 18.6 millones
• Edad 36-45: 16.9 millones
• Edad 46-55: 13.7 millones
• Edad 56-65: 13.2 millones

Poblaciones de pacientes de alto riesgo

Aspira se dirige a aproximadamente 12.5 millones de mujeres con riesgos elevados para la salud.

Categoría de riesgo	Total de pacientes	Potencial de detección
Riesgo de cáncer de ovario	4.2 millones	33.6%
Riesgo de cáncer hereditario	3.8 millones	30.4%
Condiciones ginecológicas complejas	4.5 millones	36%

Aspira Women's Health Inc. (AWH) - Modelo de negocio: Estructura de costos

Inversiones de investigación y desarrollo

Para el año fiscal 2023, Aspira Women's Health Inc. reportó gastos de I + D de $ 14.3 millones, lo que representa aproximadamente el 45% de los gastos operativos totales.

Año	Gastos de I + D	Porcentaje de gastos operativos
2023	$ 14.3 millones	45%
2022	$ 12.7 millones	42%

ESACIÓN CLÍNICA Y GASTOS DE VALIDACIÓN

Los costos de ensayos clínicos para Aspira en 2023 totalizaron $ 6.8 millones, centrándose en la detección del cáncer de ovario y las tecnologías de diagnóstico.

• Costo promedio por ensayo clínico: $ 2.3 millones
• Número de ensayos clínicos activos: 3
• Gasto del estudio de validación: $ 1.5 millones

Costos operativos de fabricación y laboratorio

Los gastos operativos de fabricación y laboratorio para 2023 fueron de $ 8,5 millones.

Categoría de costos	Cantidad
Mantenimiento del equipo	$ 2.1 millones
Suministros de laboratorio	$ 3.4 millones
Costos operativos de la instalación	$ 3.0 millones

Gastos de ventas y marketing

Los gastos de ventas y marketing para Aspira Women's Health en 2023 ascendieron a $ 9.2 millones.

• Costos del equipo de ventas directas: $ 4.6 millones
• Campañas de marketing: $ 2.7 millones
• Marketing digital y publicidad: $ 1.9 millones

Procesos de cumplimiento y certificación regulatoria

Los gastos de cumplimiento regulatorio para 2023 fueron de $ 3.6 millones.

Actividad de cumplimiento	Gastos
Costos de envío de la FDA	$ 1.2 millones
Mantenimiento de certificación	$ 1.4 millones
Tarifas legales y de consultoría	$ 1.0 millones

Aspira Women's Health Inc. (AWH) - Modelo de negocios: flujos de ingresos

Ventas y licencias de pruebas de diagnóstico

En 2023, Aspira Women's Health reportó ingresos por pruebas de diagnóstico de $ 5.3 millones. Las pruebas OVA1 y ROMA de la compañía generaron ingresos de licencia específicos de proveedores de atención médica.

Prueba de diagnóstico	Ingresos anuales (2023)	Penetración del mercado
Prueba de OVA1	$ 3.2 millones	62 Sistemas de atención médica
Prueba de romaníes	$ 2.1 millones	48 sistemas de atención médica

Reembolso de proveedores de seguros

Aspira aseguró acuerdos de reembolso con múltiples proveedores de seguros en 2023.

• Tasa de reembolso de Medicare: $ 1,250 por prueba de diagnóstico
• Cobertura de seguro privado: 85% de las principales redes de salud
• Reembolso promedio por prueba: $ 875

Tarifas de servicio clínico

Los ingresos por servicios clínicos para 2023 totalizaron $ 4.7 millones, derivados de los servicios de pruebas y consultas de diagnóstico.

Tipo de servicio	Ganancia	Volumen
Detección de cáncer de ovario	$ 3.5 millones	4.200 pruebas
Servicios de consulta	$ 1.2 millones	1.800 consultas

Subvenciones y colaboraciones de investigación

La financiación de la investigación en 2023 ascendió a $ 2.9 millones de varias fuentes.

• Subvención de los Institutos Nacionales de Salud (NIH): $ 1.5 millones
• Colaboración de investigación privada: $ 800,000
• Asociaciones de la institución académica: $ 600,000

Licencia de propiedad intelectual

La licencia de propiedad intelectual generó $ 1.6 millones en ingresos durante 2023.

Categoría de IP	Ingresos por licencias	Número de licencias
Algoritmos de prueba de diagnóstico	$ 1.2 millones	7 licencias
Tecnología de prueba molecular	$400,000	3 licencias

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Value Propositions

The core value proposition of Aspira Women's Health Inc. (AWH) centers on providing non-invasive, data-driven diagnostic tools that improve the management pathway for women with adnexal masses.

Non-invasive, blood-based ovarian cancer risk assessment

Aspira Women's Health Inc. offers a comprehensive portfolio of blood tests, OvaSuiteSM, designed to aid in the detection of ovarian cancer risk for the approximately 1.2 million American women diagnosed with an adnexal mass each year. The company reported total product revenues of $2.3 million for the third quarter of 2025, with gross margins reaching 64.1% for the nine months ended September 30, 2025.

OvaWatch: 99% negative predictive value for indeterminate masses

OvaWatch℠ is positioned for women where an initial clinical assessment indicates the mass is indeterminate or benign, supporting decisions where surgery may be premature or unnecessary. The test provides a negative predictive value of 99%.

Ova1Plus: Pre-surgical assessment of malignancy risk for adnexal masses

Ova1Plus® is a proprietary reflex process combining two FDA-cleared tests, Ova1® and Overa®, specifically for patients with adnexal masses that are planned for surgery. The combination of Ova1Plus with clinical assessment demonstrates a 96% sensitivity and a 98% negative predictive value.

The comparative performance against the standard CA-125 marker highlights the precision of Ova1Plus:

Performance Metric	Ova1Plus (with clinical assessment)	CA-125 Alone
Detection of Early-Stage Malignancy Risk (Stage I and II)	Includes detection of 63% missed by CA-125	Misses 63% of Stage I and II risk
Detection of Ovarian Cancer Risks	Detects 59% more risks missed	Baseline for comparison

Improved patient outcomes through early, precise risk stratification

The value here is in refining the management plan before an invasive procedure. The shift in strategy towards large scale health care systems and Integrated Delivery Networks (IDN's) in 2025 is showing productivity gains, with sales per full-time equivalent salesperson increasing by 167% in Q3 2025 compared to Q3 2024. The average unit price per test across the commercial portfolio grew by 7.0% year-over-year in Q3 2025.

Key clinical differentiators include:

• Ova1Plus detects 59% more ovarian cancer risks missed by CA-125 alone.
• Ova1Plus detects 63% of early-stage malignancy risk (Stage I and II) missed by CA-125.
• OvaWatch provides a 99% negative predictive value.

Cost savings for health systems by reducing unnecessary specialist referrals

Precise risk stratification directly translates to resource optimization within health systems. An example from a world-renowned IDN implementing OvaSuite™ in Q3 2025 focused on refining O-RADS 4 patient risk assessment. This implementation helped better identify low-risk patients within that cohort who did not require further imaging services or referral to a gynecologic oncologist, thereby saving critical health system resources and costs. The company is now focusing on growing profitable revenue instead of only growing specimen volume.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Customer Relationships

Dedicated assistance and clinical support for IDN integration is a core focus following the Q1 2025 strategy reset. This emphasis is on relationships with leading large scale health care systems and Integrated Delivery Networks (IDNs). As of the third quarter of 2025, this focus was highlighted by the implementation of OvaSuite™ in a world-renowned IDN to assist in refining Ovarian cancer risk assessment of O-RADS 4 patients. This IDN used OvaSuite™ protocols to better identify low-risk patients, thereby saving critical health system resources and costs.

The specialist, high-touch sales model reflects a significant restructuring. The specialist field sales team size was reduced to 7 in the second quarter of 2025, compared to 19 in the second quarter of 2024. This leaner team structure is driving substantial productivity gains. Sales generated per full-time equivalent salesperson (FTE) saw a 156% increase in the second quarter of 2025 compared to the second quarter of 2024. This metric improved further in the third quarter of 2025, realizing a 167% increase in sales per FTE compared to the third quarter of 2024. Furthermore, a compensation shift started in the third quarter of 2025 to incentivize profitable revenue growth over volume growth at any price plan.

Educational events and resources for clinicians are being scaled through strategic partnerships. The partnership with Dorsata, launched in June 2025, integrates Aspira Women's Health Inc.'s OvaSuite tests into Dorsata's platform. This platform serves over 700 providers across more than 300 practice sites in 20 states, reaching over 1.5 million patients. This partnership created approximately 28,000 new opportunities for test implementation.

Direct patient support is managed through the product portfolio designed for the 1.2+ million American women diagnosed with an adnexal mass each year. The company offers Ova1Plus®, which is a combination of two FDA-cleared tests, Ova1® and Overa®, for women planned for surgery. OvaWatch℠ is intended for use in assessing the risk of ovarian cancer for women with adnexal masses where initial clinical assessment indicates the mass is indeterminate or benign.

Here's a quick look at the sales force efficiency metrics as of late 2025:

Metric	Value (Q2 2025 vs Q2 2024)	Value (Q3 2025 vs Q3 2024)
Specialist Field Sales Team Size	7 (Q2 2025) vs 19 (Q2 2024)	Not specified
Increase in Sales per FTE	156% increase	167% increase

The reach through the Dorsata partnership as of mid-2025 includes:

• Providers served: Over 700
• Practice sites reached: Over 300
• States covered: 20
• Patients reached: Over 1.5 million
• New test implementation opportunities created: 28,000

The company is focused on delivering products that allow healthcare providers to stratify risk, facilitate early detection, and optimize treatment plans.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Channels

You're looking at how Aspira Women's Health Inc. gets its diagnostic tools, like Ova1Plus® and OvaWatch®, into the hands of clinicians and patients as of late 2025. The strategy clearly shifted to focus on efficiency and larger systems.

Specialist field sales team targeting physicians and IDNs

The direct sales channel saw a significant restructuring. The specialist field sales team is now leaner, focusing on high-value targets like large health care systems and Integrated Delivery Networks (IDNs). This change reflects a strategic pivot away from pure volume.

Here's a look at the team size and productivity metrics:

Metric	Value	Period/Context
Specialist Field Sales Team Size	7 FTEs	Q2 2025
Specialist Field Sales Team Size (Comparison)	19 FTEs	Q2 2024
Sales per FTE Increase	167% increase	Q3 2025 compared to Q3 2024
Active Prescribing Providers	4,000 providers	As of June 2025

This smaller team delivered results, though the overall OvaSuite test volume saw a dip, which management attributed to this strategic reset.

Direct sample submission to Aspira Labs, Inc.

Clinicians can use the direct referral channel, sending specimens to Aspira Labs, Inc. for processing. Aspira Labs, Inc. holds a CLIA Certificate of Accreditation and state laboratory licenses in California, Maryland, New York, Pennsylvania, and Rhode Island. They received a supplier number from the Centers for Medicare & Medicaid Services (CMS) back in 2015.

Test volume data shows the direct lab channel's recent activity:

• OvaSuite tests performed decreased 5% for the three months ended September 30, 2025.
• Volume was 5,727 tests for the three months ended September 30, 2025.
• Volume was 6,001 product tests for the same period in 2024.
• The company estimated completing approximately 24,000 tests annually as of June 2025.

The company expects revenue to pick up in the fourth quarter due to a focus on revenue-generating payers.

Aspira Synergy platform for decentralized testing access

The Aspira Synergy platform is a key channel for decentralized testing access, allowing marketing of OvaSuite tests to laboratories. While specific adoption numbers for the platform itself aren't public, its role is to facilitate testing outside the direct sales/referral loop.

The company's planned business strategy explicitly includes partnerships based on the Aspira Synergy platform.

Strategic partnerships with healthcare practice networks (e.g., Dorsata)

Strategic partnerships are a major focus for accelerated adoption, exemplified by the collaboration with Dorsata. This partnership launched a clinical workflow tool for adnexal masses on June 2, 2025.

The reach through this specific partnership is substantial:

Partnership Reach Metric	Value	Context
Dorsata Providers Reached	More than 700 women's health providers	As of June 2025
Practice Sites Reached	Over 300 practice sites	As of June 2025
States Covered	20 states	As of June 2025
Patients Impacted Annually	Over 1.5 million patients	Annually via Dorsata platform
Increase in Provider Access	700 providers	Directly from the Dorsata partnership

This partnership added a 17.5% boost to the total provider access pool at that time. It's a clear example of how Aspira Women's Health Inc. is using integrated software to drive channel efficiency.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Customer Segments

You're trying to map out exactly who Aspira Women's Health Inc. (AWH) is selling its OvaSuite diagnostics to as of late 2025. It's a focused effort, shifting away from a broader sales approach to target larger, more structured entities. Here's the quick math on the key groups they are targeting and how the numbers look based on their latest filings.

Gynecologists and gynecologic oncologists (primary prescribers)

These are the frontline clinicians who order the tests-OvaWatch and Ova1Plus-to manage patients presenting with adnexal masses. The pool of potential prescribers is substantial, though Aspira Women's Health Inc. is clearly streamlining its engagement efforts.

As of 2025, there are approximately 53,163 actively practicing Obstetricians and Gynecologists (OB/GYNs) in the United States. For the most complex cases, the specialized Gynecologic Oncologists (GOs) are critical. As of October 2025, the total number of oncologists tracked in the U.S. is over 28,000, with Gynecological Oncology representing a smaller, specialized group of about 1,445 physicians tracked within that total. This specialization highlights the need for high-impact, targeted education, which seems to be reflected in Aspira Women's Health Inc.'s reduced but seemingly more productive sales force.

The shift in commercial strategy is evident here; the specialist field sales team was down to 7 people in the second quarter of 2025, compared to 19 in the same period of 2024. However, this leaner team drove a 167% increase in sales revenue generated per full-time equivalent salesperson (FTE) in the third quarter of 2025 compared to the third quarter of 2024. That defintely suggests a move toward higher-value targets within the prescriber segment.

Women with adnexal masses (over 1.2 million US women annually)

This is the ultimate patient population that drives demand for OvaSuite. Aspira Women's Health Inc. positions its portfolio as the only comprehensive set of blood tests for this group.

The total addressable market is consistently cited as the 1.2+ million American women diagnosed with an adnexal mass each year. This is the raw volume that underpins the entire business case. The company is actively working to capture a larger share of this population, as evidenced by their partnership announced in June 2025 with Dorsata, which aimed to offer access to 1.5 Million + New Patients through Dorsata's clinical decision-support platform.

Despite the strategic focus shift, the overall test volume has seen some softness. For the nine months ending September 30, 2025, the number of tests sold decreased by 6.4% year-over-year, even as the average unit price (AUP) grew by 7.0% in the third quarter of 2025.

Large-scale health care systems and Integrated Delivery Networks (IDNs)

This segment represents the strategic pivot for Aspira Women's Health Inc. in 2025. The company is heavily emphasizing relationships with these larger entities to improve efficiency and long-term profitability.

The focus on systems is a direct response to the business model reset that began in the first quarter of 2025. This strategy was highlighted in the third quarter of 2025 with the implementation of OvaSuite in a world-renowned IDN specifically to help refine Ovarian Imaging Reporting and Data System (O-RADS) 4 patient risk assessment. Contracting at the system level is key to securing broad adoption across multiple affiliated practices.

Commercial insurance companies and government payers (Medicare)

Payer coverage dictates patient access and, ultimately, revenue realization. Aspira Women's Health Inc. works with payers to ensure their tests are covered, minimizing out-of-pocket costs for patients.

While specific 2025 coverage numbers aren't fully detailed, prior progress indicates the importance of this segment. In 2024, new Anthem contracts were reported to potentially add up to 16 million covered lives, and Medicaid coverage expanded to include fee schedules in nine states. For Medicare, reimbursement rates for MAAA (Multianalyte Assays with Algorithmic Analyses) CPT codes were extended through 2024, with the next evaluation scheduled for 2025.

The financial results show the commercial portfolio's AUP grew 11% year-over-year for Ova1Plus and 16% for OvaWatch in the second quarter of 2025, suggesting successful pricing power, likely supported by payer wins.

To keep track of where the revenue is coming from relative to the market size, here's a snapshot of the key figures we're tracking for late 2025:

Segment/Metric	Quantifiable Data Point	Source Year/Period
Annual Target Patient Population (Adnexal Masses)	1.2+ Million Women Annually	2025 Data
Total U.S. Active OB/GYNs	53,163 Physicians	2025 Data
U.S. Gynecologic Oncologists (Approx.)	1,445 Physicians	October 2025 Data
Total Product Revenue (Q3)	$2.3 Million	Q3 2025
Sales Force Size (FTEs)	7 (Specialist Field Sales)	Q2 2025
Sales Productivity (Revenue per FTE)	167% Increase vs. Q3 2024	Q3 2025
OvaWatch AUP Growth	16% Year-over-Year	Q2 2025

You should keep an eye on the test volume trend. While AUP is up, the number of tests sold for the first nine months of 2025 was down 7.3% compared to the first nine months of 2024. That volume dip, alongside the sales team reduction, confirms the transitional nature of their current commercial model.

Finance: draft 13-week cash view by Friday.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Aspira Women's Health Inc. (AWH) business model as of late 2025. Management has clearly been focused on aggressive cost containment, which shows up significantly in the year-to-date figures.

The total operating expenses for the nine months ended September 30, 2025, landed at $11.1 million. This is a substantial reduction from the $16.8 million reported for the same nine-month period last year, representing a 34.0% decrease overall. This drop is the result of targeted cuts across the board, which is exactly what you want to see when a company is resetting its commercial strategy.

Here is how the major operating expense categories shifted for the nine months ended September 30, 2025, compared to the prior year:

• Selling expenses saw a significant reduction of $3.7 million.
• General and administrative (G&A) costs were down by $1.7 million.
• Research and development (R&D) expenses were reduced by $0.4 million.

The primary driver for these reductions was headcount reductions and other cost containment measures across the organization.

When we look at the Cost of Revenue (COGS) for lab operations and materials, we can derive the total cost based on reported revenue and gross profit for the nine months ended September 30, 2025. With nine-month revenue at approximately $6.99 million and gross profit at approximately $4.5 million, the total Cost of Revenue for the nine months was approximately $2.49 million ($6.99 million minus $4.5 million). For the three months ended September 30, 2025, the Cost of product revenue was explicitly reported as $922,000.

The efficiency gains are also reflected in the gross margin performance. Gross margins for the nine months ended September 30, 2025, improved to 64.1%, up from 58.4% in the same period last year, with gross profit reaching approximately $4.5 million.

To give you a clearer picture of the expense components and their relative scale for the nine months ended September 30, 2025, based on the reported decreases:

Expense Category	Nine Months Ended Sept 30, 2025 (Total OpEx)	Year-over-Year Decrease (Nine Months)
Total Operating Expenses	$11.1 million	$5.7 million
Selling Expenses	Not Stated	$3.7 million decrease
General and Administrative (G&A) Costs	Not Stated	$1.7 million decrease
Research and Development (R&D) Expenses	Not Stated	$0.4 million decrease

G&A costs include personnel-related expenses, professional fees, and other infrastructure costs, such as legal, finance, and accounting expenses, which would encompass regulatory compliance costs.

Finance: review Q4 2025 expense run-rate against the nine-month annualized run rate by Tuesday.

Aspira Women's Health Inc. (AWH) - Canvas Business Model: Revenue Streams

The revenue streams for Aspira Women's Health Inc. are primarily derived from product sales of their diagnostic tests, supplemented by capital infusions from equity financing activities.

Product revenue is generated from the commercial portfolio, which includes non-invasive Ovarian cancer risk assessment diagnostics marketed as Ova1Plus and OvaWatch, together offered as OvaSuite.

The company has been strategically shifting focus towards growing profitable revenue, which includes efforts to maximize revenue realized from specimens performed by the lab, involving evaluation of payer contracts and billing practices.

Here are the key financial metrics related to revenue streams as of late 2025:

Revenue Metric	Amount / Detail	Date Reference
Total Product Revenue (Nine Months)	$7.0 million	Ended September 30, 2025
Trailing 12-Month Revenue (LTM)	$9.34 million	As of September 30, 2025
Q3 2025 Product Revenue	$2.31 million	For the three months ended September 30, 2025
OvaSuite Test Volume (Q3 2025)	5,727 tests	For the three months ended September 30, 2025
Average Unit Price (AUP) Growth (Q3 2025 vs. prior year)	7.0%	For the commercial product portfolio

Capital raises represent a distinct, non-operational revenue stream used to support commercial activities and working capital. In September 2025, Aspira Women's Health Inc. secured significant funding:

• Private Investment in Public Equity (PIPE) amount: $2.95 million.
• Unsolicited warrant exercise proceeds: $112 thousand.
• Total equity capital infusion announced: $3.06 million.

The reimbursement component is tied directly to the product revenue stream, driven by payer contracts and coverage decisions, such as the Novitas Local Coverage Determination (LCD) for Medicare, which supports the utilization of their tests.

The company's focus on growing profitable revenue is highlighted by the change in the commercial model, emphasizing relationships with large scale health care systems and Integrated Delivery Networks (IDN's).

The product revenue for the third quarter of 2025 was relatively flat compared to the prior year's third quarter, which was $2.26 million, despite a significant reset in business model and market strategies beginning in the first quarter of 2025.